Tillkännagivande • May 16
ToolGen Incorporated has filed a Follow-on Equity Offering in the amount of KRW 70.0854 billion. ToolGen Incorporated has filed a Follow-on Equity Offering in the amount of KRW 70.0854 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 777,000
Price\Range: KRW 90200
Transaction Features: Rights Offering New Risk • May 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (₩1.3b revenue, or US$874k). New Risk • Apr 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩1.3b revenue, or US$884k). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Reported Earnings • Mar 25
Full year 2025 earnings released: ₩4,246 loss per share (vs ₩776 profit in FY 2024) Full year 2025 results: ₩4,246 loss per share (down from ₩776 profit in FY 2024). Net loss: ₩36.8b (down ₩43.0b from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Mar 10
ToolGen Incorporated, Annual General Meeting, Mar 27, 2026 ToolGen Incorporated, Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 172, magokjungang-ro, gangseo-gu, seoul South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩42,200, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 19% over the past three years. Tillkännagivande • Feb 12
ToolGen Incorporated Appoints Dave Boncheun Koo as New Chief Legal Officer and Executive Vice President ToolGen announced the appointment of Dave Boncheun Koo, a U.S. attorney and renowned expert in international litigation and negotiation, as its new Chief Legal Officer (CLO) and Executive Vice President. This strategic move signals ToolGen's determination to aggressively enforce its global patent rights and convert its intellectual property (IP) into substantial and recurring revenue. This strategic reinforcement reflects management's unwavering commitment to translate ToolGen's robust IP portfolio into measurable royalty income and sustainable cash flow worldwide. EVP Yoori Kim, who leads ToolGen's IP business, has significantly strengthened the company's CRISPR RNP (Ribonucleoprotein) patent portfolio through 2025, equipping ToolGen with "decisive weaponry" for monetization. Furthermore, she established a dominant strategic foundation by securing a ruling from the U.S. Patent Trial and Appeal Board (PTAB) to resume Interference proceedings, reinforcing the strength and priority of ToolGen's foundational patents. ToolGen noted that her sophisticated roadmap and extensive IP groundwork have officially ushered the company into the "Revenue Generation Phase." Upon assuming his role, EVP Koo will be focused on two strategic priorities: accelerating patent monetization through global litigation and successfully concluding the U.S. Interference proceedings to be resumed. ToolGen will mobilize its full resources to pursue ongoing patent infringement actions against Vertex, which were filed sequentially in the UK (April), the Netherlands (September), and the U.S. (November) in 2025. Leveraging over 25 years of expertise in high-stakes dispute resolution at top-tier law firms like Kim & Chang, Koo will seek just compensation from global companies using ToolGen's patented technologies without authorization while simultaneously advancing favorable licensing agreements. In parallel, he will execute rigorous and persuasive advocacy in the upcoming U.S. Interference proceedings to defend ToolGen's technological leadership and foundational patent rights. Koo holds a B.A. in Molecular and Cell Biology from UC Berkeley and a J.D. from Loyola Law School. He previously served as Senior Foreign Counsel at Kim & Chang and Yulchon LLC, and as a Senior Associate at Baker & McKenzie and Paul Hastings, where he led victories and high-value settlements in major patent disputes among global ICT and biotechnology leaders, including cases involving semiconductors, displays, and next-generation light source technologies. He is a member of the California State Bar and a Registered Patent Attorney before the United States Patent and Trademark Office (USPTO). Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩60,000, the stock trades at a trailing P/E ratio of 65.2x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total returns to shareholders of 11% over the past three years. Valuation Update With 7 Day Price Move • Nov 25
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₩56,900, the stock trades at a trailing P/E ratio of 59.8x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 8.6% over the past three years. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to ₩76,200, the stock trades at a trailing P/E ratio of 78.9x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 34% over the past three years. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩56,100, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 8.8% over the past three years. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩48,550, the stock trades at a trailing P/E ratio of 48.8x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 18% over the past three years. New Risk • Sep 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (98% accrual ratio). Revenue is less than US$1m (₩882m revenue, or US$635k). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩40,150, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 30x in the Biotechs industry in South Korea. Total loss to shareholders of 32% over the past three years. Valuation Update With 7 Day Price Move • May 19
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩31,100, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past three years. New Risk • May 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (95% accrual ratio). Revenue is less than US$1m (₩891m revenue, or US$626k). Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change). Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩36,000, the stock trades at a trailing P/E ratio of 49.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total loss to shareholders of 51% over the past three years. New Risk • Mar 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 0.5% over the past year. Revenue is less than US$1m (₩999m revenue, or US$688k). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Tillkännagivande • Mar 13
ToolGen Incorporated, Annual General Meeting, Mar 28, 2025 ToolGen Incorporated, Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 172, magokjungang-ro, gangseo-gu, seoul South Korea New Risk • Dec 02
New major risk - Revenue and earnings growth Revenue has declined by 0.5% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 0.5% over the past year. Revenue is less than US$1m (₩999m revenue, or US$711k). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (7.8% increase in shares outstanding). New Risk • Nov 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (₩1.1b revenue, or US$762k). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (7.8% increase in shares outstanding). New Risk • Oct 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 32% over the past year. Revenue is less than US$1m (₩650m revenue, or US$482k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.8% average weekly change). Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Executive Director Yuri Kim was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Mar 18
ToolGen Incorporated, Annual General Meeting, Mar 31, 2021 ToolGen Incorporated, Annual General Meeting, Mar 31, 2021, at 09:00 Korea Standard Time. Location: Partel House on the 3rd floor of the Elysia Knowledge center 173 Digital-ro, Geumcheon-gu Seoul South Korea Agenda: To approve the financial statement; to appoint directors; to approve of the compensation limit for directors; to approve of the compensation limit for auditors; and to discuss other matters. Is New 90 Day High Low • Feb 02
New 90-day high: ₩123,000 The company is up 87% from its price of ₩65,700 on 04 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 20% over the same period. Is New 90 Day High Low • Dec 29
New 90-day high: ₩105,500 The company is up 53% from its price of ₩69,000 on 29 September 2020. The South Korean market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 02
New 90-day high: ₩83,000 The company is up 19% from its price of ₩69,500 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period. Is New 90 Day High Low • Oct 05
New 90-day high: ₩79,300 The company is up 44% from its price of ₩55,000 on 07 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period.